The biopharmaceutical company Biopharma, the investement of Quarter Partners, begins to conduct EIA (enzyme immunoassay) tests for availability of COVID-19 antibody assay for all plasma donors, EIA testing will identify those who have the disease in a latent form.
“Biopharma purchased 12,000 EIA tests manufactured by Roche and on May 18 we will begin testing donors for antibodies on our hardware base,” Kostiantyn Yefymenko, the co-owner of the company, said on his Facebook page.
He recalled that Biopharma has begun collecting plasma from donors who have undergone COVID-19.
Biopharma has begun the development of a hyperimmune immunoglobulin based on plasma of people who had COVID-19, this drug can be effective for specific treatment of COVID-19.
Biopharma, the investement of Quarter Partners, is a Ukrainian biotechnology company, the only plant in Eastern Europe that has modern technology, has been manufacturing and developing drugs from donated plasma for almost 50 years.